Regulus floats after slashing IPO price but partner placements add to tally
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics sold 11.25 million shares of common stock at $4 per share on 4 October - one-third of its earlier expectation of $10 to $12 per share - when its initial public offering debuted on the Nasdaq, but the company raised $70 million in total thanks to a concurrent private placement of 6.25 million shares with its partner AstraZeneca.